RESI Boston: Insight from China Strategic Partners on Cross-Border Opportunities

3 Aug

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

An increasing number of Chinese biopharma companies are entering the global stage and changing the dynamics in life science innovations. In 2016, Simcere Pharma made a splash by hosting a life sciences startup competition across East and West coast. This year, not long after Qilu Pharma launched its 25,000 square-feet incubator in Brighton, Luye Pharma also opened its new Boston R&D Center.

As these Chinese firms are setting foot in North America, they typically hire industry veterans with multinational pharma experiences to spearhead their business development efforts. These professional deal-makers not only are equipped with deep domain knowledge, but they develop a unique perspective on cross-border opportunities for biopharma innovators.

At RESI Boston, entrepreneurs are invited to the China Strategic Partners Panel to learn about where market opportunities and challenges are, and how to collaborate with Chinese corporations. The speakers include:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: